Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by PTO PR Newswire GLEN ALLEN, Va., Sept. 12, 2013 GLEN ALLEN, Va., Sept. 12, 2013 /PRNewswire/ --Star Scientific, Inc. (NASDAQ: STSI) announced that the U.S. Patent and Trademark Office ("PTO") issued a Notice of Allowance on September 3, 2013 to Rock Creek Pharmaceuticals, Inc., its wholly owned subsidiary, in Application No. 13,477,295, covering anatabine citrate, the active component in the company's Anatabloc® products. A Notice of Allowance, issued by the PTO, is a notification that an applicant is entitled to a patent. The patent is expected to issue within approximately two months. (Logo: http://photos.prnewswire.com/prnh/20130319/PH79245LOGO ) The allowed '295 application discloses an improved process for synthesizing anatabine that facilitates larger scale, commercial production, as well as novel salts of anatabine including anatabine citrate. An initial patent, U.S. Patent No. 8,207,346, based on the same disclosure, was awarded on June 26, 2012 and covered claims for the improved process for synthesizing anatabine. The claims allowed in the '295 application cover anatabine citrate per se as well as formulations containing anatabine citrate. The company, through Rock Creek, continues to pursue several additional patent applications covering dietary formulations containing anatabine, and methods of administering anatabine for the nutritional management of disorders associated with unhealthy levels of inflammation. Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K and 10K/A for the fiscal year ended December 31, 2012 and our quarterly reports on Form 10-Q for the quarters ended March 31, 2013 and June 30, 2013. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. About Star Scientific Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism and lifestyle. Through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, a cosmetic facial cream and facial serum, as well as the development of other nutraceuticals and pharmaceuticals. The company also continues to pursue the licensing of the technology behind its proprietary StarCured® curing process and its related products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, and an Executive, Scientific & Regulatory Affairs office in Washington, DC. Contact: Talhia T. Tuck Vice President, Communications and Investor Relations Star Scientific, Inc. (202)887-5100 email@example.com SOURCE Star Scientific, Inc. Website: http://www.starscientific.com
Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by PTO
Press spacebar to pause and continue. Press esc to stop.